/

Società

Am

Non verificato

Amgen

Di cosa scriviamo

Ecologia/Salute ambientaleFarmaceuticaIndustriaMedicina - VarieSalute

5 comunicati stampa

Guarda tutti i comunicati

29/07/2026

Salute

Fitness

Medicina - Varie

Ecologia/Salute ambientale

Agricoltura

POSITIVE CHMP OPINION SUPPORTS BROADER USE OF AMGEN'S REPATHA® BEFORE A FIRST HEART ATTACK OR STROKE

Fonte

Emittente

1.00

0

Press Release cover image

01/06/2026

Salute

Fitness

Medicina - Varie

Ecologia/Salute ambientale

Agricoltura

EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Fonte

Emittente

1.00

0

07/05/2025

Industria

Scienza

Biotecnologia

Farmaceutica

Ottica

Salute

Medicina - Varie

Amgen’s TEPEZZA®▼ (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom

Fonte

Emittente

1.00

0

Press Release cover image

29/01/2025

Farmaceutica

Sanità

Biologia

EUROPEAN COMMISSION APPROVES BLINCYTO® IN PHILADELPHIA CHROMOSOME-NEGATIVE CD19-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN THE CONSOLIDATION PHASE

Fonte

Emittente

1.00

0

06/01/2025

Industria

Scienza

Biotecnologia

Farmaceutica

Oncologia

Salute

Sanità

Amgen’s IMDYLLTRA®▼ (tarlatamab) Granted a Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in the United Kingdom

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0